[1]
|
Institute of Medicine. Clinical Practice Guidelines We Can Trust.[M]. Washington (DC):National Academies Press (US), 2011. |
[2]
|
U.S. Food and Drug Administration. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices-Guidance for Industry and Food and Drug Administration Staff[EB/OL].(注明发布日期)[注明引用日期].https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-wor ld-evidence-support-regulatory-decision-making-medical-devices. |
[3]
|
U.S. Food and Drug Administration. Framework for FDA's Real-World Evidence Program[EB/OL]. https://www.fda.gov/media/124748/download. |
[4]
|
国家药品监督管理局.真实世界数据用于医疗器械临床评价技术指导原则(征求意见稿)[EB/OL].(注明发布日期)[注明引用日期].https://www.cmde.org.cn/CL0066/20139.html. |
[5]
|
国家药品监督管理局. http://www.nmpa.gov.cn/WS04/CL2138/373175.html. |
[6]
|
SHERMAN R E, ANDERSON S A, DAL PAN G J, et al. Real-World Evidence-What Is It and What Can It Tell Us?[J]. The New England journal of medicine, 2016, 375:2293-2297. |
[7]
|
NEW J P, BAKERLY N D, LEATHER D, et al. Obtaining real-world evidence:the Salford Lung Study[J]. Thorax, 2014, 69:1152-1154. |
[8]
|
CONCATO J, CORRIGAN-CURAY J. Real-World Evidence-Where Are We Now?[J]. The New England journal of medicine, 2022, 386:1680-1682. |
[9]
|
U.S. Food and Drug Administration. 21st Century Cure Act[EB/OL].(注明发布日期)[注明引用日期]. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-curesact. |
[10]
|
U.S. Food and Drug Administration. Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drugs and Biologics Guidance for Industry[EB/OL].https://www.fda.gov/media/124748/download. |
[11]
|
国家药品监督管理局.国家药监局药审中心关于发布《真实世界研究支持儿童药物研发与审评的技术指导原则(试行)》的通告(2020年第22号)[EB/OL].(注明发布日期)[注明引用日期].https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200901104448101.html. |
[12]
|
ALONSO-COELLO P, IRFAN A, SOL I, et al. The quality of clinical practice guidelines over the last two decades:a systematic review of guideline appraisal studies[J]. Quality&safety in health care, 2010, 19:e58. |
[13]
|
BABJUK M, BURGER M, CAPOUN O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)[J]. European urology, 2022, 81:75-94. |
[14]
|
CHANG S S, BOORJIAN S A, CHOU R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer:AUA/SUO Guideline[J]. The Journal of urology, 2016, 196:1021-1029. |
[15]
|
MORI K,MIURA N,BABJUK M,et al. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma:A systematic review[J]. Urologic oncology, 2020, 38:774-782. |
[16]
|
CHAMIE K, SAIGAL C S, LAI J, et al. Compliance with guidelines for patients with bladder cancer:variation in the delivery of care[J]. Cancer, 2011, 117:5392-5401. |
[17]
|
POSEN A, BENKEN S, KALUZNA S D, et al. Poor guideline adherence in a real-world evaluation of hypertensive emergency management[J]. The American journal of emergency medicine, 2022, 51:46-52. |
[18]
|
CABANA M D, RAND C S, POWE N R, et al. Why don't physicians follow clinical practice guidelines?A framework for improvement[J]. Jama, 1999, 282:1458-1465. |
[19]
|
JIN Y H, TAN L M, KHAN K S, et al. Determinants of successful guideline implementation:a national cross-sectional survey[J]. BMC medical informatics and decision making, 2021, 21:19. |
[20]
|
WONG G W, MIRAVITLLES M, CHISHOLM A, et al. Respiratory guidelines——which real world?[J]. Annals of the American Thoracic Society, 2014, 11 Suppl 2:S85-91. |
[21]
|
GUYATT G H, OXMAN A D, VIST G E, et al. GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ (Clinical research ed), 2008, 336:924-926. |
[22]
|
HERLAND K, AKSELSEN J P, SKJ NSBERG O H, et al. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?[J]. Respiratory medicine, 2005, 99:11-19. |
[23]
|
HOFFMAN S N, TENBROOK J A, WOLF M P, et al. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty:one-to eight-year outcomes[J]. Journal of the American College of Cardiology, 2003, 41:1293-1304. |
[24]
|
W. BRETT M T H, U. GULLER, H.-R. ZERKOWSKI. CABG vs. PCI in coronary artery disease:what is the evidence?[J]. Card Surg Today, 2006, 2:43-55. |
[25]
|
GRAPOW M T, VON WATTENWYL R, GULLER U, et al. Randomized controlled trials do not reflect reality:real-world analyses are critical for treatment guidelines![J]. The Journal of thoracic and cardiovascular surgery, 2006, 132:5-7. |
[26]
|
KENNEDY-MARTIN T, CURTIS S, FARIES D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results[J]. Trials, 2015, 16:495. |
[27]
|
CHEW S Y, KOH M S, LOO C M, et al. Making Clinical Practice Guidelines Pragmatic:How Big Data and Real World Evidence Can Close the Gap[J]. Annals of the Academy of Medicine, Singapore, 2018, 47:523-527. |
[28]
|
HAYWARD R S. Clinical practice guidelines on trial[J]. CMAJ:Canadian Medical Association journal=journal de l'Association medicale canadienne, 1997, 156:1725-1727. |
[29]
|
周奇,董冲亚,王业明,等.循证医学理念在指导临床研究与实践中的作用:基于对抗病毒药物治疗新型冠状病毒肺炎的思考[J].中国循证医学杂志, 2022, 22:373-379. |
[30]
|
SCHNEEWEISS S, PATORNO E. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments[J]. Endocrine reviews, 2021, 42:658-690. |
[31]
|
U.S. Food and Drug Administration. FDA expands approved use of metastatic breast cancer treatment to include male patients[EB/OL].(注明发布日期)[注明引用日期].https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635276.htm?utm_campaign=040419_PR_FDA% 20expands% 20use% 20of% 20breast% 20cancer% 20treatment% 20to% 20include% 20male% 20patients&utm_medium=email&utm_source=Eloqua (2019). |
[32]
|
KHAN O, WILLIAMS M J, AMEZCUA L, et al. Multiple sclerosis in US minority populations:Clinical practice insights[J]. Neurology Clinical practice, 2015, 5:132-142. |
[33]
|
WILLIAMS M J, AMEZCUA L, OKAI A, et al. Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis:3-Year Results from ESTEEM[J]. Neurology and therapy, 2020, 9:483-493. |
[34]
|
KLEEBERG U R, LINDE H, G NTHER G, et al. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia:Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature[J]. Anticancer research, 2016, 36:2827-2838. |
[35]
|
BEASLEY R, HOLLIDAY M, REDDEL H K, et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma[J]. The New England journal of medicine, 2019, 380:2020-2030. |
[36]
|
ALBERTSON T E, MURIN S, SUTTER M E, et al. The Salford Lung Study:a pioneering comparative effectiveness approach to COPD and asthma in clinical trials[J]. Pragmat Obs Res, 2017, 8:175-181. |
[37]
|
MAGNUSSEN H, DISSE B, RODRIGUEZ-ROISIN R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD[J]. The New England journal of medicine, 2014, 371:1285-1294. |
[38]
|
CHEN Y, WANG C, SHANG H, et al. Clinical practice guidelines in China[J]. BMJ (Clinical research ed), 2018, 360:j5158. |
[39]
|
KEARON C, AKL E A, COMEROTA A J, et al. Antithrombotic therapy for VTE disease:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141:e419S-e496S. |
[40]
|
KONSTANTINIDES S V, TORBICKI A, AGNELLI G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism[J]. European heart journal, 2014, 35:3033-3069, 3069a-3069k. |
[41]
|
WANG C, ZHAI Z, YANG Y, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism:a randomized, multicenter, controlled trial[J]. Chest, 2010, 137:254-262. |
[42]
|
FRANKLIN J M, GLYNN R J, MARTIN D, et al. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making[J]. Clinical pharmacology and therapeutics, 2019, 105:867-877. |
[43]
|
彭晓霞,舒啸尘,谭婧,等.基于真实世界数据评价治疗结局的观察性研究设计技术规范[J].中国循证医学杂志, 2019, 19:779-786. |
[44]
|
CORTESE S, PANEI P, ARCIERI R, et al. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD):Data from the Italian National ADHD Registry[J]. CNS drugs, 2015, 29:865-877. |
[45]
|
谭婧,刘兴会,孙鑫.基于真实世界数据的疾病管理研究[J].协和医学杂志, 2019, 10:284-288. |
[46]
|
CAMM A J, LIP G Y, DE CATERINA R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association[J]. European heart journal, 2012, 33:2719-2747. |
[47]
|
ANDRADE A A, LI J, RADFORD M J, et al. Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation[J]. Journal of general internal medicine, 2015, 30:777-782. |
[48]
|
QUANSTRUM K H, HAYWARD R A. Lessons from the mammography wars[J]. The New England journal of medicine, 2010, 363:1076-1079. |
[49]
|
SHAUGHNESSY A F, COSGROVE L, LEXCHIN J R. The Need to Systematically Evaluate Clinical Practice Guidelines[J]. Journal of the American Board of Family Medicine:JABFM, 2016, 29:644-648. |
[50]
|
STEELS S, VAN DER ZANDE M, VAN STAA T P. The role of real-world data in the development of treatment guidelines:a case study on guideline developers'opinions about using observational data on antibiotic prescribing in primary care[J]. BMC health services research, 2019, 19:942. |
[51]
|
National Institue for Health and Care Excellence. NICE strategy 2021 to 2026-Dynamic, Collaborative, Excellent[EB/OL].(注明发布日期)[注明引用日期].https://www.nice.org.uk/about/who-we-are/corporate-publications/the-nice-strategy-2021-to-2026. |
[52]
|
COLLINS R, BOWMAN L, LANDRAY M, et al. The Magic of Randomization versus the Myth of Real-World Evidence[J]. The New England journal of medicine, 2020, 382:674-678. |
[53]
|
LEVY R I. Currently available lipid-lowering agents[J]. Hospital practice (Office ed), 1988, 23 Suppl 1:14-21. |
[54]
|
COLLINS R, REITH C, EMBERSON J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy[J]. Lancet (London, England), 2016, 388:2532-2561. |
[55]
|
RIMM E B, STAMPFER M J, ASCHERIO A, et al. Vitamin E consumption and the risk of coronary heart disease in men[J]. The New England journal of medicine, 1993, 328:1450-1456. |
[56]
|
STAMPFER M J, HENNEKENS C H, MANSON J E, et al. Vitamin E consumption and the risk of coronary disease in women[J]. The New England journal of medicine, 1993, 328:1444-1449. |
[57]
|
Heart Outcomes Prevention Evaluation Study Investigators, YUSUF S, DAGENAIS G, et al. Vitamin E supplementation and cardiovascular events in high-risk patients[J]. The New England journal of medicine, 2000, 342:154-160. |
[58]
|
刘晓清,孙晓川.真实世界证据[J].协和医学杂志, 2017, 8:305-310. |
[59]
|
TUNIS S R, STRYER D B, CLANCY C M. Practical clinical trials:increasing the value of clinical research for decision making in clinical and health policy[J]. Jama, 2003, 290:1624-1632. |
[60]
|
谭婧,程亮亮,王雯,等.患者登记研究的策划与患者登记数据库构建:基于观察性设计的真实世界研究[J].中国循证医学杂志, 2017, 17:1365-1372. |
[61]
|
唐立,康德英,喻佳洁,等.实效性随机对照试验:真实世界研究的重要设计[J].中国循证医学杂志, 2017, 17:999-1004. |
[62]
|
孙鑫,谭婧,唐立,等.基于真实世界证据的上市后药品评价技术框架体系:思考与建议[J].中国循证医学杂志, 2018, 18:277-283. |
[63]
|
BOOTH C M, KARIM S, MACKILLOP W J. Real-world data:towards achieving the achievable in cancer care[J]. Nat Rev Clin Oncol, 2019, 16:312-325. |
[64]
|
徐浩,史大卓,刘保延,等.以临床实践数据为导向构建中西医结合临床指南的设想[J].中国中西医结合杂志, 2009, 29:544-547. |
[65]
|
王雯,刘艳梅,谭婧,等.回顾性数据库研究的概念、策划与研究数据库构建[J].中国循证医学杂志, 2018, 18:230-237. |